Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT01995188 (Clinical Trial/ Lifastuzumab vedotin / anti-NaPi2b ADC / RG-7599 / DNIB0600A)

Study Title
A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Patients With Ovarian Cancer (NCT01995188)

Trial Description
This open-label, multicenter, phase Ib study will evaluate the safety and pharmacokinetics of DNIB0600A ( also known as lifastuzumab vedotin / anti-NaPi2b ADC / RG-7599 / DNIB0600A) in patients with platinum-sensitive ovarian cancer. The maximum tolerated dose of intravenously infused DNIB0600A in combination with carboplatin will be determined in escalating dose cohorts. The combination of DNIB0600A and carboplatin will then be evaluated with and without bevacizumab [Avastin] in two dose expansion cohorts.

This trial is sponsored by Genentech. [1]

Study Data

  • Condition:
  • Interventions:
    • Drugs used in this trial
      • DNIB0600A (Lifastuzumab vedotin; anti-NaPi2b ADC; RG-7599; DNIB0600A)
      • bevacizumab (Avastin®;Genentech, Inc.)
      • carboplatin
  • Phase: I
  • Estimated Enrollment: 42
  • Start: December 2013
  • Estimated Completion: September 2016
  • Last verified: July 2015

Study Schematic 

(Coming soon)

Click here to Return to Drug map


Last Editorial review: July 10, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar